We scan new podcasts and send you the top 5 insights daily.
Many therapeutic target proteins naturally bind DNA, producing massive false positive readouts in DNA encoded library screens. Assigning dozens of distinct DNA barcodes to identical small molecules reveals whether target enrichment is driven by specific DNA nucleotide motifs rather than the attached chemical.
Gordian Biotechnology embeds unique genetic "barcodes" into hundreds of different gene therapies. This transforms gene therapy from a treatment modality into a high-throughput screening tool, allowing them to test many potential drugs simultaneously inside a single living animal and trace which ones worked.
Instead of digital screening, Sethera Therapeutics generates vast physical libraries of hundreds of trillions of unique peptides within a small test tube. Each peptide is given a unique barcode, enabling researchers to test them against real biological targets and identify effective molecules from infinitesimally small quantities.
The challenge with pooled screening is isolating the single best clone. A novel approach uses a CRISPR activation system that specifically targets the winning clone's unique DNA barcode. This activates a selectable marker, enabling the high-precision extraction of the desired cell line for monoclonal expansion.
By labeling each cell with a unique DNA barcode, all clones can be grown together in a single, manufacturing-relevant bioreactor. This shifts the core challenge from laborious individual cell measurements to a high-throughput sequencing and data analysis task, dramatically increasing efficiency and data richness.
Because DNA encoded libraries are built combinatorially from building blocks, millions of molecules differ by only one or two changes. This structured variation enables machine learning models to isolate exactly which chemical fragments drive target binding while keeping the rest of the molecule constant.
Recludix succeeded in drugging SH2 domains, a target class abandoned in the 90s, by integrating five modern technologies. This platform includes proprietary DNA-encoded libraries, machine learning, a selectivity tool, novel crystallography methods, and a pro-drug approach to ensure cell permeability, demonstrating the complex approach needed for modern drug discovery breakthroughs.
Traditional drug discovery groups run DNA encoded libraries against isolated, difficult targets in hope of a single hit, missing systematic library quirks. Screening every library across hundreds of targets surfaces batch-to-batch manufacturing variations, chemical motifs, and assay failure modes that single screens never detect.
Traditionally, vector design and cell line development are sequential steps requiring intermediate tests. By screening a mixed pool of candidates with DNA barcodes directly in a bioreactor, these stages can be overlapped, accelerating the timeline from initial design to identifying a high-performing manufacturing clone.
Despite testing millions of compounds, high-throughput screening methods suffer from enormous false-positive rates. The actual predictive value for a re-synthesized molecule is extremely low, creating an opening for high-fidelity AI models to provide cleaner, more reliable predictions.
Designing therapeutics with immense combinatorial complexity is impossible through rational design alone. The optimal approach is to first use human biological hypotheses to narrow the vast search space. Then, employ large-scale screening and data analysis to optimize within that constrained space, navigating variables too complex for human comprehension.